相关实验视频

Updated: Jun 20, 2026

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

供体血清SMARCAL1度预测了心脏移植中初级移植功能障碍

Seyedhossein Aharinejad¹, Olena Andrukhova, Matthias Gmeiner

¹Department of Cardiothoracic Surgery, Medical University of Vienna, Austria. seyedhossein.aharinejad@meduniwien.ac.at

|September 16, 2009

概括

供体血清SMARCAL1是预测心脏移植后初级移植功能障碍 (PGD) 的有希望的生物标志物. 在大动脉交叉紧之前的升高水平表明PGD的高风险,使早期干预成为可能.

科学领域:

心脏病学心脏病学
移植免疫学移植免疫学
生物标志物发现发现

背景情况:

主要移植功能障碍 (PGD) 是心脏移植后的一个关键并发症.
确定可靠的供体预测因子对于PGD预防策略至关重要.

研究的目的:

调查SMARCAL1血清度作为心脏捐赠者的PGD预测标记.
评估SMARCAL1用于PGD预测的诊断准确性.

主要方法:

用ELISA测量了336名心脏捐赠者的血清SMARCAL1度,在大动脉交叉紧 (ACC) 之前和之后进行了测量.
根据特定的血液动力学和功能标准来定义PGD.
使用接收器操作特征 (ROC) 曲线分析来确定预测性能.

主要成果:

在捐赠者中观察到显著增加的SMARCAL1血清度,这些捐赠者的移植物发展为PGD.
在ACC之前的SMARCAL1水平>或=1.25 ng/mL准确预测了PGD,具有96%的灵敏度和88%的特异性 (AUC=0.988).
具有SMARCAL1 < 1.25 ng/mL的捐赠者有97%的PGD无结果.

结论:

供体血清SMARCAL1是一种敏感和特定的非侵入性标记物,用于评估心脏移植质量.
SMARCAL1有可能指导临床决策,并改善心脏移植中PGD预防.

更多相关视频

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

相关概念视频

Kidney Transplant I: Introduction

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...